Open Label Pharmacokinetic Study of SAR302503 in Subjects With Renal Impairment
Status:
Completed
Trial end date:
2013-07-01
Target enrollment:
Participant gender:
Summary
Primary Objective:
To study the effect of mild, moderate and severe renal impairment on the pharmacokinetics of
SAR302503.
Secondary Objective:
To assess the tolerability of SAR302503 given as a single 300 mg dose in subjects with mild,
moderate and severe renal impairment and in matched subjects with normal renal function.